Emergent BioSolutions Inc. (EBS) bonds
EBSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/3072% below fair value
$5.79−0.10 (-1.70%)
Close on Nov 13, 2026Market cap $296.87MP/E –Yield –
Debt
Borrowings on the balance sheet, Sep 30, 2026
Total debt
$507.70M
Long-term debt
Net debt
$332.00M
After $175.70M of cash
Implied interest rate
9.60%
FY2025 interest ÷ average debt
Interest coverage
1.7×
FY2025 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
When the debt comes due
Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2025
From the debt maturity table in the annual report (filing). “Later” is everything due after year five.
Notes and loans outstanding
As tagged in Emergent BioSolutions's 10-Q for the period ended Jun 30, 2026
| Issue | Coupon | Matures | Carrying value |
|---|---|---|---|
| Senior Unsecured Notes Due August 2028 | 3.87% | Aug 31, 2028 | $439.70M |
Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size | Drawn | Expires |
|---|---|---|---|
| Term loan due 2029 | – | $0 | 2029 |
| Delayed Draw Term Loan | $75.00M | – | – |
| Initial Term Loan | $150.00M | $150.00M | – |
| Revolving Loans | $5.00M | – | – |
| Term Loan | $250.00M | $150.00M | – |
| Uncommitted Incremental Facility | $200.00M | – | – |
See a number that looks wrong?